ruxolitinib,navtemadlin
incyte,kartos therapeutics,novartis
['mpnsm', '#mpn', 'navtemadlin']
exciting first results from the navtemadlin add on trial expertly presented by #johnmascarenhas at #eha23! svr35 and tss50 rates of 32% each at 24 w about as good as any reported in this setting! #sergeverstovsek #mpnsm 
Associate Professor, Leukemia at MD Anderson; myeloproliferative neoplasm expert, NCCN panelist. Tweets reflect my own views; not necessarily my institution's.